Late intervention with the small molecule BB3 mitigates postischemic kidney injury

Area of Science:

• Nephrology
• Pharmacology
• Regenerative Medicine

Background:

• Ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI), often requiring renal replacement therapy.
• Late administration of therapeutics for AKI remains a significant clinical challenge.

Purpose of the Study:

• To investigate the therapeutic potential of BB3, a small molecule activator of the hepatocyte growth factor (HGF) pathway, in a rat model of renal IRI.
• To determine if BB3 can confer benefits when administered 24 hours after the initial ischemic event.

Main Methods:

• Rats subjected to renal ischemia-reperfusion were treated with BB3 24 hours post-ischemia.
• Evaluated survival rates, urine output, serum creatinine, and blood urea nitrogen.
• Assessed kidney injury markers (KIM-1, NGAL), tubular apoptosis, and necrosis.
• Analyzed molecular markers of HGF pathway activation (p-cMet, p-Akt) and apoptosis (Bcl-2).

Main Results:

• BB3 treatment significantly improved survival and augmented urine output.
• BB3 reduced serum creatinine and blood urea nitrogen levels compared to controls.
• Histological analysis revealed reduced tubular injury and apoptosis, with enhanced tubular regeneration in BB3-treated kidneys.
• BB3 treatment increased renal cMet and Akt phosphorylation and upregulated Bcl-2 expression.

Conclusions:

• The kidney remains amenable to pharmacotherapy even 24 hours after ischemia-reperfusion.
• Late intervention with the small molecule BB3 activates the HGF signaling pathway, conferring significant therapeutic benefits in established IRI.
• These findings support the clinical investigation of BB3 for delayed graft function in kidney transplant recipients.